Monograph Reform

Browse Monograph Reform Content

CHPA is pleased to see FDA’s long-awaited draft guidance on innovative approaches for greater consumer access to nonprescription medicines, and applauds FDA’s focus on patient safety as a top priority.

Jul 17, 2018

CHPA is pleased to see FDA’s long-awaited draft guidance on innovative approaches for greater consumer access to nonprescription medicines, and applauds FDA’s focus on patient safety as a top priority.

Jul 17, 2018

Today, the U.S. House of Representatives passed H.R. 5333, the Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018.

Jul 16, 2018

We are encouraged by the ongoing, bipartisan momentum behind this reform and look forward to seeing the legislation move forward in the House as well as the Senate.

May 9, 2018

Today, the United States Senate Health, Education, Labor and Pensions (HELP) Committee approved S. 2315, the Over-the-Counter Drug Safety, Innovation, and Reform Act by a 22-1 vote.

Apr 4, 2018

CHPA released the following statement today by President and CEO, Scott Melville, applauding the introduction of The Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2018

Mar 19, 2018

CHPA strongly supports the OTC Monograph system as a balanced framework for regulating OTC medicines containing ingredients with a proven history of safe use.

Sep 13, 2017

CHPA congratulates the House of Representatives on the passage of the Food and Drug Administration Reauthorization Act of 2017.

Jul 12, 2017

CHPA strongly supports the OTC Monograph System, but we believe that policy reforms could make the system more flexible, responsive, and accommodating to innovation.

Jul 12, 2016

Filter Results